RRM2 and breast cancer: Of these signatures, Knudsen et al. (20) and Malorni et al. (19), both of which were designed for predicting palbociclib resistance, shared 17 genes each with RBNSig-BC including 11 genes (KIF2C, RAD54L, KIFC1, ORC1, CDCA8, CDC45, FAM83D, CDC20, CENPA, RRM2, and PIF1) that were present in all three signatures.